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Abstract
Background: Synovial infiltration of monocytes is commonly associated with inflammation in rheumatoid arthritis
(RA). Toll-like receptors (TLRs) are innate sensors that recognize cell debris and microbial components in host, a
process contributing to maintain chronic inflammation in RA. We assessed the expression levels of TLR2 and TLR9
in monocyte subsets of active RA patients and characterized their cytokine profiles in response to synthetic and
viral TLR2 and TLR9 agonists, including Epstein-Barr virus (EBV) which is suspected to contribute to RA symptoms.
Methods: Prevalence of monocyte subsets CD14++ CD16−, CD14+ CD16+ and CD14low CD16++ was evaluated in
blood and synovial fluids of active RA patients and levels of TLR2 and TLR9 in monocyte subsets were measured by
flow cytometry. Enriched monocytes derived from RA patients and healthy donors were stimulated in vitro with
synthetic TLR2 and TLR9 agonists and with EBV particles or viral DNA. Intracellular cytokine profiles were
determined in respective monocyte subsets. Finally, the presence of EBV genome was evaluated by real-time
PCR in blood and synovial monocytes of RA patients.
Results: Numbers of CD14+ CD16+ and CD14low CD16++ were found to increase in blood of RA patients compared to
healthy controls, while all three subsets were detected in synovial fluids. TLR2 is abundantly expressed on blood and
synovial CD14++ CD16− and CD14+ CD16+ monocytes from RA patients. Levels of TLR9 were increased on all three
subsets of blood monocytes but markedly enhanced in monocytes isolated from synovial fluids. Compared to healthy
controls, CD14++ CD16− monocytes of RA patients displayed an enlarged capacity to produce proinflammatory
cytokines after stimulation with synthetic TLR2 and TLR9 agonists while both CD14++ CD16− and CD14+ CD16+
monocytes showed increased response to EBV stimulation. The presence of EBV genome was also detected in
monocytes and neutrophils of a significant proportion of patients.
Conclusion: Patients with active RA show an increased expression of TLR2 and TLR9 on monocyte subsets and display
higher production of inflammatory cytokines in response to TLR agonists. The presence of EBV genome in monocytes
and neutrophils reinforces the suspected role of the virus in the exacerbation of RA symptoms.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease
that is characterized by chronic joint inflammation that
progressively leads to cartilage and bone destruction. It
is generally believed that genetic factors are involved in
the susceptibility to develop RA, but evidence also sug-
gests that environmental factors, including viral infec-
tions, may have an influence on the incidence of disease.
RA is characterized by synovial hyperplasia and inflam-
mation resulting from a massive infiltration of inflam-
matory cells, including monocytes and neutrophils [1].
These cells play a key role in the progression of RA
through the production of proinflammatory cytokines,
leading to the development of an inflammatory environ-
ment and immune cell recruitment in the joints.
In humans, monocytes are a heterogeneous cell popu-
lation composed of three distinct subsets based on their
expression of CD14 and CD16 [2]. The CD14++ CD16−
classical subset, which is the most prominent of all cir-
culating monocytes, is rapidly recruited to the sites of
inflammation and appears to act as phagocytic scavenger
cells and regulators of inflammation [3, 4]. The second
monocyte subset expresses levels of both CD14 and
CD16 (CD14+ CD16+). It is referred to as intermediate
monocytes and is suggested to play a proinflammatory
role, being increased in blood from patients with acute
inflammation [5, 6]. The third subset comprises nonclas-
sical monocytes that express low levels of CD14 and
high levels of CD16 (CD14low CD16++), which are often
referred to as patrolling monocytes [7]. The two CD14+
subsets are thus recognized to expand in various inflam-
matory diseases and are suggested to play a significant
role in disease processes [8, 9]. In RA patients, the fre-
quency of monocytes expressing CD16 antigen (inde-
pendently of the level of expression of CD16) was found
to be increased in blood and synovial fluids [10, 11].
Toll-like receptors (TLRs) are expressed in all subsets
of monocytes. These receptors function as detectors to
recognize microbial motifs, and several debris and intra-
cellular molecules released from necrotic cells [12, 13].
Triggering of TLRs by various stimuli leads to the acti-
vation of signaling pathways that culminate in the pro-
duction of proinflammatory cytokines, a process driving
aberrant and chronic inflammation in the joints of RA
patients (reviewed in [14]). The role of TLRs in arthritis
is underlined by the fact that resident and infiltrating
cells in the inflamed joint were found to express various
TLRs. While their functional roles are not yet clearly de-
fined, different studies have attempted to identify which
TLRs are associated with the severity of RA. For ex-
ample, TLR3 and TLR4 have been found highly
expressed in synovial fibroblasts from RA patients [15].
It was also suggested that RA patients carrying a TLR4
variant, Asp299Gly, have decreased susceptibility to RA
[16]. Expression levels of TLR2 were found increased in
CD14+ CD16+ blood monocytes isolated from RA pa-
tients compared to healthy controls [17] and such abun-
dant expression of TLR2 was also detected in the
synovial tissue of RA patients compared to patients with
osteoarthritis [18, 19]. Monocytes and differentiated
macrophages isolated from RA patients also have been
found to have increased expression of TLR2 as com-
pared to those from other forms of inflammatory arth-
ritis [20]. While these observations suggest that TLR2
might contribute to sustaining inflammation in the
joints, its role in the pathogenesis of RA remains to be
clarified.
Little is known about the stimuli capable of triggering
signals that result in synovial tissue damage. In addition
to cell debris, viral infection has long been speculated to
be a potential factor in RA. Several viruses have been
suspected for many years to contribute to potentiate RA
symptoms, including Epstein–Barr virus (EBV) [21, 22],
cytomegalovirus (CMV) [23], parvovirus B19 [24] and
hepatitis C virus [25], to name a few. EBV is still by far
considered as a leading candidate to exacerbate auto-
immune diseases, including RA [22, 26, 27]. Indeed,
EBV has high prevalence in the population and persists
in latently infected cells with continuous viral reactiva-
tion. This virus has also the potential to modulate the
immune system and to infect monocytes and neutrophils
[28, 29], two key cellular populations activated in RA.
The results presented in this study demonstrate that
monocyte subsets isolated from patients with active RA
express elevated levels of both TLR2 and TLR9 and have
enhanced responsiveness to synthetic and viral TLR2
and TLR9 agonists compared to controls. A significant
fraction of blood monocytes and neutrophils from these
patients were found to contain the EBV genome, sup-
porting the possible contribution of this virus in the ex-
acerbation of inflammation in susceptible RA patients.
Methods
Ethics statement
Experiments were performed in accordance with an in-
ternal review board-approved protocol at le CHU de Qué-
bec – Université Laval (Québec, Canada) (#105.05.06). All
healthy donors and patients gave their written informed
consent.
Cohort recruitment
Twenty-three patients with active RA and long-standing
disease (>4 years) were recruited for this study. Seven of
them had a large synovial knee effusion when recruited.
Clinical features of selected RA patients are presented in
Table 1. When sampled, all patients had flare-up with
high scores in the 28 swollen-joints count (14.4 ± 8.1)
and most (16/23) had a high disease activity score in 28
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joints-erythrocyte sedimentation rate (DAS 28-ESR)
(≥5.1). Twelve EBV-seropositive healthy volunteers who
did not experience inflammatory diseases and were not
suffering from infectious diseases when recruited, are re-
ferred to as healthy controls. The presence of anti-EBV
antibodies, e.g., anti-early antigen (EA), anti-Epstein–
Barr nuclear antigen 1 (EBNA-1) and anti-viral capsid
antigen (VCA), was tested in plasma of all RA patients
and healthy controls by ELISA (DIASource Immuno-
assay, Louvain-La-Neuve, Belgium). Serologic results
show that patients with active RA present abnormal ele-
vated anti-EBV titers compared to seropositive healthy
volunteers (data not shown).
Isolation of monocytes and neutrophils from blood and
synovial fluids
Plasma from healthy donors and RA patients and syn-
ovial fluids (SF) from RA patients were isolated by cen-
trifugation. Mononuclear cells were isolated using Ficoll
density gradient (Wisent, Québec, Canada) as reported
[30], and were first separated from the lymphocyte
population by cell adherence on Petri dishes. Monocyte
subsets were analyzed by flow cytometry based on their
expression of CD14 and CD16 using CD14-PE-Cy7
(M5E2) and CD16-A647 (3G8) antibodies (BD Biosci-
ences, San Jose, CA, USA) (purity approximatley 99 %)
(BD FACSAria, BD Biosciences). Classical, intermediate
and nonclassical monocytes were specifically identified
by selective gating strategy as follows: CD14++ CD16−
(classical), CD14+ CD16+ (intermediate) and CD14low
CD16++ (nonclassical). We found no evidence to indi-
cate that blood dendritic cells (<1 %) contribute signifi-
cantly to subpopulations of circulating monocytes [31].
Monocytes were enriched from synovial fluids with the
same approach. Blood neutrophils from RA patients and
healthy volunteers were isolated as previously described
[28, 32]. Neutrophil purity (>98 %) was determined
using intracellular staining with an anti-myeloperoxidase
(MPO) antibody (5B8) (BD Biosciences). When indi-
cated, the presence of cytokines (IL-1β, IL-6, TNFα,
MCP-1) in synovial fluids from RA patients was deter-
mined using Cytometric Bead Array system (CBA
FlexSet, BD Biosciences, San Jose, CA, USA).
Flow cytometry analysis
Enriched monocyte subsets (identified as detailed above)
and neutrophils were washed twice in Hanks Balanced
Salt Sodium (HBSS; Wisent) and stained with TLR2-
fluorescein isothiocyanate (FITC) (TL2.1) or TLR9-FITC
(5G5) antibodies (Hycult Biotech, Uden, The
Netherlands). Cells were fixed and permeabilized prior
to TLR9 staining [30] and subsequently washed twice
and resuspended in HBSS supplemented with 1 % bo-
vine serum albumin (BSA; Wisent) for cytometry ana-
lysis. Expression of TLR2 and TLR9 was analyzed on
each monocyte subset and neutrophils using a BD SORP
LSR II and data analyzed with the BD FACS Diva (BD
Biosciences) and FlowJo (FlowJo, LLC, Ashland, OR,
USA) software.
Cell treatment and intracellular cytokine staining
For intracellular cytokine staining (ICCS), peripheral
blood mononuclear cells (PBMC) from healthy volun-
teers and RA patients were isolated using Ficoll density
gradient. After an overnight resting, cells were washed
and stimulated in vitro as indicated with EBV particles
(multiplicity of infection of 1) or EBV DNA (40 μg/ml)
[30, 33]. As positive TLR2 and TLR9 controls, cells were
stimulated with lipoteichoic acid (LTA) (10 μg/ml) and
type-B CpG-2006 (40 μg/ml), respectively. After a 5-
hour stimulation in the presence of BD GolgiPlug™ (pro-
tein transport inhibitor) (BD Biosciences), stimulated
cells were harvested and cytokine expression levels were
assessed by intracellular flow cytometry [34]. Supernatants
were sporadically tested for protein transport blockage
and cytokine production was not found in supernatants,
confirming the effective cytokine blockage. Cells were
stained with CD45-PerCP-Cy5.5 (2D1) (eBioscience, San
Diego, CA, USA), CD91-FITC (A2-MR-α2), CD14-PE-
Cy7 (M5E2) and CD16-A700 (3G8) (BD Biosciences) to
discriminate between monocyte subsets, as detailed in the
standardized flow cytometry assay [35]. After cell mem-
brane permeabilization using BD Intrasure permeabilizing
solution (BD Biosciences), intracellular staining was
performed to detect proinflammatory cytokines with
the following antibodies: IL-1β-Α647 (JK1B-1) (BioLe-
gend, San Diego, CA, USA), which recognized both pro-
and active isoforms of IL-1β, IL-6-BV421 (MQ2-13A5),
MCP-1-PE (5D3-F7) (BD Biosciences) and TNFα-BV711
Table 1 Clinical characteristic of selected patients
Characteristics Values in patients with
rheumatoid arthritis (n = 23)
Gender male/female, n 2/21
Age, years, mean ± SD 57.0 ± 10.8
Disease duration, y, mean ± SD 5.0 ± 7.3
Swollen joints, 0–28 14.4 ± 8.1
CRP, ± SD, mg/l 13.0 ± 12.7
ESR, ± SD, mm/h 19.4 ± 16.4
RF (+), n (%) 9 (39 %)
ACPA (+), n (%) 8 (35 %)
RF & ACPA (+) n (%) 7 (30 %)
Disease activity score in 28 joints-CRP 5.3 ± 1.5
DAS activity score in 28 joints-ESR 5.7 ± 1.5
Data are mean ± SD unless stated otherwise. CRP C-reactive protein, ESR
erythrocyte sedimentation rate, RF rheumatoid factor, ACPA anti-citrullinated
protein antibodies
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(Mab11) (BioLegend). Cell samples were analyzed using
the BD SORP LSRII and data analyzed using BD FACS-
Diva software (BD Biosciences).
DNA extraction and real-time PCR analysis
Enriched blood monocytes and neutrophils were resus-
pended in TRIzol Reagent (Life Technologies, Burlington,
ON, Canada) and DNA extraction was performed accord-
ing to the manufacturer’s instructions. DNA was amplified
using GoTaq qPCR MasterMix (Promega, Madison, WI,
USA) on a Rotor Gene 3000 (Montreal Biotech Inc.,
Montreal, QC, Canada). Purified EBV was obtained from
EBV B-cell lineage B95.8 as described [30, 33]. EBV
dsDNA was isolated and purified as reported [30]. The fol-
lowing primers were used to detect BamHI-W EBV gene
[29] (NCBI reference sequence NC_007605, Human her-
pes virus 4 type 1 complete genome, http://www.
ncbi.nlm.nih.gov/nuccore/82503188) (forward: 5′-GCG
CCA TTT TGT CCC CAC GC-3′ and reverse: 5′-TGG
CCT AGC AAC GCG AAC CC-3′) and human
glyceraldehyde-3-phosphate-deshydrogenase (hGAPDH)
gene (forward: 5′-ATG CTG CAT TCG CCC TCT TAA
TGG-3′ and reverse: 5′-AGG CGC CCA ATA CGA CCA
AAT CTA-3′). Purified DNA from EBV-positive B95.8 B-
cell line (Advanced Biotechnologies Inc., Columbia, MD,
USA) was used as positive control for BamHI-W
amplification.
Statistical analysis
Nonparametric one-way analysis of variance (Kruskal–
Wallis test) followed by Dunn’s post-hoc test were used
to compare multiple groups. The nonparametric Stu-
dent’s t test (Mann–Whitney) (unpaired, two-tailed) was
performed for two experimental groups. Analyses were
performed using GraphPad Prism version 6.00 for Win-
dows (GraphPad Software, La Jolla, CA, USA).
Results
CD14+ CD16+ and CD14low CD16++ monocyte levels are
increased in blood from patients with active RA
Three distinct monocyte subsets are now defined in
humans, two of them expressing the CD16 marker.
While classical monocytes were suggested to play a sig-
nificant role in the progression of several diseases, the
trafficking of separately defined intermediate (CD14+
CD16+) and nonclassical (CD14low CD16++) monocytes
during RA was not fully investigated. We have first de-
termined by flow cytometry the proportion of these
three monocyte subsets in blood of patients with active
RA compared to healthy volunteers. Monocyte subsets
isolated from blood and synovial fluids of RA patients
were gated as P1 (CD14++ CD16−), P2 (CD14+ CD16+)
and P3 (CD14low CD16++) (Fig. 1a). Gating of P2 and P3
subsets from SF of RA patients was found to slightly
differ from blood cell gating, presumably due to their
morphology and respective environment. Compared to
healthy volunteers, we observed a reduced proportion of
CD14++ CD16− in blood from RA patients and a signifi-
cant increase of both CD14+ CD16+ and CD14low CD16++
monocytes (Fig. 1a–b). These results are in line with
previous reports showing that the whole blood CD16+
monocyte population increases in patients with active
RA [10, 36]. We have also evaluated the proportion of
monocyte subsets that migrate into the joints of RA pa-
tients. In patients (n = 7) with knee joint effusion, we
detected an elevated proportion of CD14++ CD16− and
CD14+ CD16+ monocytes but a very low number of
CD14low CD16++ monocytes (Fig. 1a, c). These results
indicate that while all subsets of monocytes are de-
tected in SF from RA patients, the classical CD14++
CD16− and the intermediate CD14+ CD16+ monocytes
appear to be predominantly recruited in the joints.
Monocyte subsets from patients with active RA express
increased levels of TLR2 and TLR9
Monocytes are known to drive inflammation in tissues
where they are recruited. They can recognize various li-
gands through TLRs, a process leading to the production
of several proinflammatory mediators. Although en-
hanced expression of TLR2 and TLR9 was demonstrated
in the synovium of active RA patients, their distribution
on all three monocyte subsets remains to be investi-
gated. We first determined the expression levels of
TLR2 and TLR9 on all three blood monocyte subsets
isolated from RA patients and healthy controls. Staining
of blood monocyte subsets with anti-TLR2 monoclonal
antibody clearly showed increased fluorescence intensity
levels of TLR2 on all three subsets of monocytes of pa-
tients with active RA compared to monocytes of healthy
controls (Fig. 2a–b). When looking at TLR2 intensity
levels on monocytes isolated from synovial fluids, expres-
sion levels were also detected on all three subpopulations
of monocytes but found particularly high on CD14++
CD16− and CD14+ CD16+ monocytes (Fig. 2a, c). The in-
tensity levels of TLR9 were significantly increased on all
three monocyte subsets (Fig. 3a–b). Furthermore, TLR9
expression profiles were also enhanced on monocyte sub-
populations isolated from synovial fluids of patients with
active RA (Fig. 3a, c). These data suggest that expression
of TLR9 is regulated during active RA and that TLR9
could play a significant role as an innate sensor contribut-
ing to sustained inflammation in the joints of patients with
active RA.
Increased expression of TLR2 and TLR9 on neutrophils of
RA patients
As neutrophils express several TLRs including TLR2
and TLR9, we wanted to determine as we did for
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monocytes, whether the expression of these TLRs is also
increased on neutrophils isolated from blood and syn-
ovial fluids from RA patients. The fluorescence intensity
level of TLR2 was not significantly affected on blood
neutrophils from RA patients and remained comparable
to blood neutrophils obtained from healthy controls
(Fig. 4a–b) which express low levels of TLR2 [37, 38].
Cytometry analysis of RA blood neutrophils also demon-
strated modest expression of TLR9, which was similar to
neutrophils obtained from healthy volunteers (Fig. 4a–b).
In contrast, TLR2 and TLR9 expression profiles on neu-
trophils isolated from synovial fluids were quite different
(Fig. 4a, c). Indeed we observed that both TLR2 and TLR9
expression levels were significantly increased in synovial
neutrophils. While these results cannot be compared to
healthy controls for obvious reasons, TLR2 and TLR9
levels on synovial neutrophils were still higher than blood
neutrophils isolated from either healthy controls or RA
patients. We thus reasoned that such increased expression
of TLR2 and TLR9 might reflect a more sustained activa-
tion of neutrophils induced by the release of TLR2/TLR9
agonists inherent to the RA synovial environment. Taken
together, these results could suggest that following their
migration into the joints, neutrophils may present en-
hanced responsiveness to TLR2 and TLR9 ligands.
Enhanced responsiveness of monocyte subsets of
patients with active RA to synthetic and viral TLR2 and
TLR9 agonists
Increased expression levels of TLR2 and TLR9 in mono-
cytes from RA patients may indicate that these cells are
potentially more sensitive to TLR2 and TLR9 ligand
stimulation. We next wanted to determine whether in-
creased expression of TLR2 and TLR9 on different
monocyte subsets could also correlate with enhanced
production of inflammatory cytokines when stimulated
with TLR2 and TLR9 ligands. To evaluate which mono-
cyte population contributes to cytokine production in
RA patients, isolated mononuclear cell populations of
RA patients and healthy controls were stimulated in
vitro with synthetic and viral TLR2 agonists, LTA and
EBV particles [33] and with TLR9 agonists, CpG and
EBV DNA [30]. Viral infection has for a long time been
proposed to contribute to exacerbate RA symptoms in
susceptible patients. We chose EBV components as viral



















































































Fig. 1 Levels of monocyte subsets in blood and synovial fluids from rheumatoid arthritis (RA) patients. a Flow cytometry analysis of CD14++ CD16−
(P1), CD14+ CD16+ (P2) and CD14low CD16++ (P3) blood monocytes from healthy controls and RA patients and of synovial monocytes from
RA patients. Data are cell populations of representative donors. b Percentage of blood monocyte subsets from healthy controls and RA patients. Black
bars healthy donors, gray bars RA patients. c Percentage of monocyte subsets from synovial fluid of RA patients. Data represent the mean ± standard
error of the mean. Striped bars RA patient synovial fluids (SF): *p ≤0.05 and ***p ≤0.001
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and TLR9 [30, 33] and because the recruited RA pa-
tients had abnormal elevated anti-EBV titers. After
5 hours of stimulation, ICCS was performed on IL-1β,
IL-6, TNFα and MCP-1 on the three distinct monocyte
subsets and expression levels was monitored by flow cy-
tometry. This approach was chosen over sorted mono-
cyte populations because it would be technically difficult
to purify each monocyte subset with the small blood
samples obtained from RA patients.
Stimulation of RA monocytes with the synthetic TLR2
agonist, LTA, induced an increase of IL-6, IL-1β and
TNFα expression in CD14++ CD16− subsets when com-
pared to healthy donors (Fig. 5a). IL-1β expression was
also increased in the CD14+ CD16+ subset upon LTA
stimulation, but levels were equivalent in both healthy
and RA patients. LTA treatment did not induce the syn-
thesis of monocyte chemoattractant protein-1 (MCP-1)























































Fig. 2 Toll-like receptor2 (TLR2) expression levels are increased in blood and synovial monocyte subsets of rheumatoid arthritis (RA) patients.
a Flow cytometry analysis of TLR2 expression on blood monocyte subsets from healthy controls and RA patients. TLR2 expression for synovial
monocyte subsets is also shown for RA patients. TLR2-positive cells appear in green (P1), blue (P2) or purple (P3). Gray histograms represent internal
negative controls. Data are cell populations of representative donors. b TLR2 expression on each blood monocyte subset of healthy controls and
RA patients is presented as mean fluorescence intensity (MFI) (mean ± standard error of the mean (SEM)). Black bars healthy donors, gray bars RA
patients. c TLR2 expression in the monocyte subsets from synovial fluids of RA patients is presented as MFI (mean ± SEM). Striped bars RA patient
synovial fluids: *p ≤0.05 and **p ≤0.01
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patient monocytes responded distinctly to the second
TLR2 agonist, EBV virions. Indeed, intracellular expres-
sion IL-1β and MCP-1 was increased in both CD14++
CD16− and CD14+ CD16+ subsets of RA patients when
compared to healthy donors (Fig. 5b). This result is con-
sistent with findings that show that EBV binding to
monocytes leads to MCP-1 production [33]. Our obser-
vations show that EBV virions also lead to an increase in
the production of IL-1β in CD14++ CD16− and CD14+
CD16+ in arthritic patients (Fig. 5b). This result entails
that IL-1β expression is probably mediated by envelope
protein recognition by surface TLRs, most likely TLR2.
We must also consider that the IL-1β gene could be ac-
tivated following viral entry into cells [39].
Interestingly, our results show that healthy and RA pa-
tients did not produce TNFα in response to EBV. This is
consistent with results that demonstrated that infectious
EBV strongly inhibit TNFα in primary mononuclear cells
and in myelo-monocytic cell lines [40]. Furthermore, we





















































Fig. 3 Increased level of toll-like receptor 9 (TLR9) on circulating and synovial monocyte subsets of rheumatoid arthritis (RA) patients. a Flow
cytometry analysis of TLR9 expression on blood monocyte subsets from healthy controls and RA patients. TLR9 expression for synovial monocyte
subsets is also shown for RA patients. TLR9 expression appears in green (P1), blue (P2) or purple (P3). Gray histograms represent internal negative
controls. Data are cell populations of representative donors. b TLR9 expression on blood monocyte subsets from healthy controls and RA
patients are presented as mean fluorescence intensity (MFI) (mean ± standard error of the mean (SEM)). Black bars healthy donors, gray bars RA patients.
c TLR9 expression in the monocyte subsets of RA patient synovial fluids is presented as MFI (mean ± SEM). Striped bars RA patient synovial fluids: *p ≤0.05
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completely eliminated the CD14low CD16++ monocytes,
as witnessed by flow cytometry. The basis for this select-
ive depletion of CD14low CD16++ monocyte is unknown,
but it was unmistakable for both healthy and RA sam-
ples. In all, these results suggest that classical CD14++
CD16− and CD14+ CD16+ monocyte subsets have been
sensitized and can participate more robustly to the pro-
inflammatory cytokines response when stimulated with
TLR2 agonist, including EBV particles.
Stimulation with TLR9 agonist, CpG, induced a
heightened intracellular expression of both IL-1β and
TNFα in CD14+ CD16+ monocyte subsets, where their
respective cytokine expression was similar for both
healthy and RA patients (Fig. 6a). We also observed a
significant increase in MCP-1 production in the CD14++
CD16− monocyte population from RA patients. In the
current settings, stimulation with EBV DNA did not ap-
pear to induce a broad proinflammatory cytokine re-
sponse in the respective monocyte subset (Fig. 6b).
Together, these results show that monocytes from RA
patients display a heightened inflammatory response
state, as illustrated by increased production of proin-
flammatory cytokines, when stimulated with TLR2 and
TLR9 ligands. They also underline the importance of
B C
A
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Fig. 4 Expression of toll-like receptor 2 (TLR2) and TLR9 in neutrophils of rheumatoid arthritis (RA) patients. a Flow cytometry analysis of TLR2 and
TLR9 expression in neutrophils isolated from blood of healthy controls and RA patients and synovial fluids of RA patients. TLR2 and TLR9 expression is
represented by red histograms whereas negative control is represented by gray histograms. Data are neutrophils of representative donors. b TLR2 and
TLR9 expression on blood neutrophils from healthy controls and RA patients are presented as mean fluorescence intensity (MFI) (mean ± standard error
of the mean (SEM)). Black bars healthy donors, gray bars RA patients . c TLR2 and TLR9 expression on synovial fluid neutrophils from RA
patients are presented as MFI (mean ± SEM). Striped bars RA patient synovial fluids
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both monocyte subsets, CD14++ CD16− and CD14+
CD16+, as producers of inflammatory mediators follow-
ing recognition of TLR ligands. The presence of IL-6
and MCP-1 detected in synovial fluids from RA patients
is in line with the expression profile measured by intra-
cellular staining (Table 2).
EBV genome is present in monocytes and neutrophils of
patients with active RA
For many years, EBV has been suspected to contribute
to the exacerbation of inflammation in susceptible pa-
tients suffering from auto-immune diseases like RA.
Because we have observed that monocytes of patients
with active RA have enhanced responsiveness to EBV,
this prompted us to evaluate whether circulating
monocytes and neutrophils of RA patients harbor the
EBV genome. First, we measured elevated levels of anti-
EBV antibodies in sera from RA patients compared to
the EBV-seropositive control group, suggesting that
viral reactivation occurs in these patients (data not
shown). Cellular DNA was next extracted from
enriched blood monocytes and neutrophils from RA
patients and from seropositive healthy volunteers and
the presence of the EBV genome was evaluated by real-
time PCR analysis of the BamHI-W repeated sequence
of the viral genome as we previously reported [29]. The


















Fig. 5 Intracellular cytokine expression in monocyte subsets of rheumatoid arthritis (RA) patients after stimulation with toll-like receptor (TLR2)
agonists. Mononuclear cells from RA patients and healthy donors were enriched and stimulated with lipoteichoic acid (LTA) (a) and Epstein–Barr
virus (EBV) particles (TLR2 ligands) (b) in vitro. After a 5-hour stimulation, the stimulated cells were harvested and cytokine expression levels were
assessed by intracellular flow cytometry. Briefly, cells were stained with CD45, CD91, CD14 and CD16, permeabilized and intracellular staining was
performed on proinflammatory cytokines: IL-6, IL-1β, TNFα and monocyte chemoattractant protein-1 (MCP-1). Intracellular cytokine expression is
shown for classical CD14++ CD16−, intermediate CD14+ CD16+ and nonclassical CD14low CD16++ monocyte subsets. Gray non-stimulated samples,
Blue healthy donors, red RA patients. Representative cytometry histograms are representative of ten donors
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presence of the EBV genome was detected in circulat-
ing monocytes from eleven RA patients tested and in
blood neutrophils from five of these patients (Table 3).
Synovial monocytes from three patients were found
positive for the presence of the EBV genome, one of
them also having EBV-positive neutrophils, suggesting
that both monocytes and neutrophils could contribute
to the transport of the virus into the joints of those
patients.
Discussion
Some patients with active RA have fluctuations of dis-
ease symptoms and transient flare-up episodes during
treatment, suggesting intermittent activation of cells or
immune pathways involved in driving inflammation. Cir-
cadian and circannual biological rhythms are known to
influence the pathophysiology and clinical symptoms of
RA [41]. Clinical symptoms and disease activity are in-
fluenced by seasonal changes [42] through the
CpG Stimulation


















Fig. 6 Intracellular cytokine expression in monocyte subsets from rheumatoid arthritis (RA) patients following toll-like receptor 9 (TLR9) stimulation.
Mononuclear cells from RA patients and healthy donors were enriched and stimulated with CpG-2006 (a) and Epstein–Barr virus (EBV) DNA
(TLR9 ligands) (b) in vitro. Gating strategy is described in Fig. 5. Intracellular cytokine level for IL-6, IL-1β, TNFα and monocyte chemoattractant
protein-1 (MCP-1) are shown for all three subsets of monocytes. Gray non-stimulated samples, Blue healthy donors, red RA patients. Representative
cytometry histograms are representative of ten donors
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alternation of sunlight and darkness. For example, the
low levels of vitamin D in winter and spring are associ-
ated with increased risks of disease onset and severity of
disease activity and outcomes [43]. Vitamin D regulates
both innate and adaptive immunity, potentiating the in-
nate response but suppressing adaptive immunity [44].
Its synthesis is increased in monocytes/macrophages in
the presence of bacterial and viral infections, a
phenomenon that contributes to initiate innate defense
against pathogens, including viruses. The onset and se-
verity of RA might also be due to the seasonality of
infections.
Previous studies have indicated that monocytes ex-
pressing a CD16+ phenotype are expanded in the blood
of patients with inflammatory diseases like RA, making
these cell populations a plausible marker of disease ac-
tivity [8, 45]. However, those studies have investigated
CD16+ monocytes as a unique population, thus masking
the reliable functions of each CD16+ subset. In the
present study, we have separately defined all three sub-
sets of monocytes in order to evaluate their individual
role in active RA. We have observed a significant in-
crease of both subsets of CD16+ monocytes (CD14+
CD16+, CD14low CD16++) in blood from patients with
active RA. On the other hand, the decrease of classical
blood monocytes (CD14++ CD16−) could reflect a con-
stant recruitment of these cells to the inflamed tissue in
order to regulate local inflammation. The marked pres-
ence of classical and intermediate (CD14+ CD16+)
monocytes in synovial fluids from patients presenting
with knee effusion emphasize the role played by these
two monocyte subsets in the inflamed tissues of RA
patients.
The increased expression of CD14+ CD16+ and
CD14low CD16++ monocyte subsets in patients with ac-
tive RA may suggest the progression of the disease [10,
46, 47], but may also reflect the activation of the mono-
cyte population. This hypothesis is in line with the ex-
pression levels of TLR2 and TLR9 detected on
individual monocyte subsets. In fact, staining for TLR2
revealed a marked increased expression of TLR2 on
blood and synovial CD14++ CD16− and CD14+ CD16+
monocytes from RA patients and to a lesser extent on
blood CD14low CD16++ monocytes. We also detected an
enhanced expression of TLR9 on all three subsets of
monocytes regardless of their origin (blood or synovial
fluids). While the exact roles of TLR2 and TLR9 in RA
remain speculative, it has, however, been suggested that
the presence of TLR2 in synovial tissue and macro-
phages of patients with clinically active disease contrib-
ute to symptom severity via the production of
inflammatory cytokines [18, 20]. Another important
issue is that synovial fibroblasts from RA patients release
chemokines in response to TLR2 triggering [48]. The
presence of TLR2 on CD16+ blood monocytes is also
proposed to contribute to the production of TNFα in
RA patients [17]. Therefore, the enhanced expression of
TLR2 that we detected on monocytes from RA patients
may indeed contribute to the secretion of various media-
tors, including chemotactic factors involved in the re-
cruitment of blood cells into the joint.
Little is known about the role of TLR9 in RA. How-
ever, the therapeutic effect of hydroxychloroquine, an in-
hibitor of TLR9 signaling, suggests that TLR9 might
participate in the severity of inflammatory symptoms in
RA [49]. We found that all blood and synovial monocyte
subsets, particularly CD14++ CD16− and CD14+ CD16+
monocytes, express significant levels of TLR9, which
highlights a potential contribution of this TLR in RA.
Interestingly, we also detected a marked increase of
TLR9 on synovial neutrophils from RA patients. Neutro-
phils being essential to control invading agents and elim-
inate cell debris, such increased expression of TLR9 in
neutrophils may thus suggest that they are potentially
more susceptible to producing inflammatory mediators
following their migration into the joint.
The higher levels of TLR2 and TLR9 detected on dif-
ferent monocyte subsets from RA patients were in line
with the production of cytokines by these cells in re-
sponse to stimulation with TLR2 and TLR9 ligands. In-
deed, both TLR2 agonists tested were found to induce
an increase in proinflammatory cytokine production in
cells isolated from RA patients compared to healthy
Table 2 Cytokine detection in plasma and synovial fluids of RA
patients
Blood Synovial fluids
IL-6 23.6 ± 5.3 11484.5 ± 3960.2
IL-1β N.D. 4.0 ± 1.6
TNF α N.D. 2.8 ± 0.4
MCP-1 87.2 ± 11.1 975.4 ± 691.9
Concentrations (pg/ml) of cytokines (IL-6, IL-1β, TNFα, monocyte chemoattractant
protein-1 (MCP-1) were monitored by cytometric bead array in plasma and
synovial fluids from rheumatoid arthritis (RA) patients. Presence of cytokines
was not detected in plasma from healthy volunteers. Data are mean ± standard
error of the mean. N.D. not detected
Table 3 Detection of the Epstein–Barr virus (EBV) genome in
monocytes and neutrophils from rheumatoid arthritis (RA)
patients
Blood Synovial fluids
Cell populations Healthy controls RA patients RA patients
Monocytes 1/12 11/23 3/7
Neutrophils 0/12 5/23 1/7
DNA was isolated from monocytes and neutrophils and analyzed by real-time
PCR for the presence of BamH1-W sequence in the EBV genome as detailed in
“Methods”. Results are presented as number of positive samples over all
donors tested
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controls. To refine the functional characterization and
to identify the monocyte subsets that produce these cy-
tokines, we performed intracellular measurement in
each RA subset of monocytes. Our results clearly show
that proinflammatory cytokines were found mostly in
CD14++ CD16− and CD14+ CD16+ monocyte subsets
confirming the importance of these subsets in the
TLR2-dependent proinflammatory events. Interestingly,
our results also indicate that both TLR2 agonists induce
a distinct immune response cytokine profile. On the
one hand, LTA triggers the production of IL-1β in both
CD14++ CD16− and CD14+ CD16+ monocytes, while
production of IL-6 and TNFα is restricted to CD14++
CD16− monocytes. Likewise, EBV virions also induce
clear proinflammatory cytokine secretion profiles with
increased levels of IL-1β and MCP-1 by both CD14++
CD16− and CD14+ CD16+ monocytes.
The distinct cytokine profiles of monocyte subsets in
response to LTA stimulation presume that these cells
should also be sensitive to many other endogenous
TLR2 agonists released in inflamed joints and also that
regulation of cytokine genes may differ from one subtype
of monocytes to another. The massive detection of intra-
cellular MCP-1 in two RA monocyte subsets following
EBV stimulation suggests that these cells could poten-
tially trigger the release of MCP-1, a potent chemokine
involved in the recruitment of inflammatory monocytes,
once they are in the synovial environment. As expected,
EBV stimulation did not induce the activation of the
TNF gene, being recognized as a suppressor of TNF syn-
thesis [40, 50].
Stimulation with the TLR9 agonist CpG showed a dis-
tinct intracellular cytokine profile compared to the
stimulation with TLR2 agonists. Indeed, production of
IL-1β and TNFα was mainly detected in CD14+ CD16+
monocytes, while modest production of MCP-1 was de-
tected in CD14++ CD16− monocytes. EBV DNA treat-
ment failed to accumulate detectable levels of
intracellular cytokines, confirming that in fact, the cyto-
kines tested are mainly regulated through the triggering
of TLR2. Unfortunately, no significant change in cyto-
kine profiles were observed in CD14low CD16++ mono-
cyte but this might reflect the limitation of the
experimental approach where very low numbers of these
cells are isolated from patient tissues.
The enhanced secretion of cytokines by monocyte sub-
sets stimulated with EBV virions might reflect the sus-
ceptibility of these cells to viral components. In this
regard, we detected the presence of EBV genome in
monocytes from a large proportion of patients with ac-
tive RA. Neutrophils from five of those RA patients were
also found to contain EBV genome, indicating that both
these cell populations may contribute to the dissemin-
ation of viral particles in patients with active RA, as
previously suggested [28, 29]. Therefore, as EBV is rec-
ognized by TLR2 and TLR9 and can also enhance TLR9
expression following its entry into monocytes [30, 33],
triggering of these sensors by released viral particles may
thus contribute to sustained cellular activation and ab-
normal production of inflammatory mediators. Our ob-
servations also reinforce the link that infectious agents
may lead to exacerbation of arthritis and disease flares in
susceptible patients. Indeed, despite good adherence to
disease-modifying antirheumatic drugs (DMARDs), such
as methotrexate and hydroxychloroquine, some patients
have severe intermittent fluctuations in the clinical activ-
ity of the disease.
In light of our observations, we suggest that both
monocyte subsets, e.g., CD14++ CD16− classical and
CD14+ CD16+ intermediate monocytes play an active
role in the severity of inflammation in active RA and
that CD14++ CD16− classical monocytes could also
contribute to amplify the inflammation by secreting
proinflammatory cytokines and potent chemoattrac-
tants. We assume that levels of both TLR2 and TLR9
are appealing markers in determining the level of acti-
vation of monocytes. It is thus plausible to consider a
scenario that may engage a sequence of at least two
TLRs: TLR2 may generate the first signal following rec-
ognition of self molecules released from damaged cells,
and TLR9 creates a feedback loop by binding DNA mo-
tifs internalized by phagocytes like neutrophils and
macrophages. We presume that TLR2 and TLR9 can
also be activated by viral components (like EBV) in the
synovial compartment, a mechanism causing exacerba-
tion of arthritis in susceptible RA patients. The com-
bined activation of TLR2 and TLR9 may thus
contribute to sustain inflammation in the joints of RA
patients by inducing a wide range of chemokines and
cytokines. In the absence of efficient mechanisms that
can regulate such an amplification loop, an excessive
production of inflammatory mediators may result in in-
creased severity of RA symptoms. Overall, our results
in RA patients with a high disease activity score high-
light the combined potential of TLR2 and TLR9 in the
pathophysiology of RA and suggest the possible in-
volvement of an opportunistic pathogen like EBV in
the exacerbation of RA symptoms.
Conclusions
Results presented in this study demonstrate that blood
and synovial monocyte subsets isolated from patients
with active RA have high levels of TLR2 and TLR9 and
increased production of inflammatory cytokines in re-
sponse to synthetic and viral TLR2 and TLR9 agonists.
Such mechanisms may thus contribute to exacerbation
of arthritis in patients with active RA.
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